{"items": "61", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/general/biotech/24/11/41949259/aileron-therapeutics-investigational-drug-shows-encouraging-action-in-lung-fibrosis", "time_published": "20241113T180449", "authors": ["Vandana Singh"], "summary": "On Wednesday, Aileron Therapeutics Inc ( NASDAQ; ALRN ) revealed topline data from Cohort 2 of its Phase 1b trial of safety and tolerability of inhaled LTI-03 for idiopathic pulmonary fibrosis ( IPF ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/13/ALRN.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.159494, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.258351", "ticker_sentiment_score": "0.068011", "ticker_sentiment_label": "Neutral"}]}, {"title": "Are Medical Stocks Lagging Sensus Healthcare  ( SRTS )  This Year?", "url": "https://www.zacks.com/stock/news/2281347/are-medical-stocks-lagging-sensus-healthcare-srts-this-year", "time_published": "20240530T134009", "authors": ["Zacks Equity Research"], "summary": "Here is how Sensus Healthcare, Inc. (SRTS) and Aileron Therapeutics, Inc. (ALRN) have performed compared to their sector so far this year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default116.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.289826, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SRTS", "relevance_score": "0.766141", "ticker_sentiment_score": "0.532339", "ticker_sentiment_label": "Bullish"}, {"ticker": "ALRN", "relevance_score": "0.448316", "ticker_sentiment_score": "0.151897", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights", "url": "https://www.globenewswire.com/news-release/2024/05/15/2882983/28652/en/Aileron-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html", "time_published": "20240515T211300", "authors": ["Aileron Therapeutics", "Inc."], "summary": "Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis ( IPF ) patients with positive trends observed in seven of the eight biomarkers evaluated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.993856"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.126563, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.106659", "ticker_sentiment_score": "0.074286", "ticker_sentiment_label": "Neutral"}]}, {"title": "Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics  ( ALRN )  Looks Ripe for a Turnaround", "url": "https://www.zacks.com/stock/news/2269557/down--3629-in-4-weeks-heres-why-aileron-therapeutics-alrn-looks-ripe-for-a-turnaround", "time_published": "20240507T133505", "authors": ["Zacks Equity Research"], "summary": "The heavy selling pressure might have exhausted for Aileron Therapeutics (ALRN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default305.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.150143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.489394", "ticker_sentiment_score": "0.165799", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million", "url": "https://www.globenewswire.com/news-release/2024/05/03/2875352/28652/en/Aileron-Therapeutics-Announces-Closing-of-Underwritten-Registered-Direct-Offering-of-up-to-Approximately-40-Million.html", "time_published": "20240503T200500", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.999491"}], "overall_sentiment_score": 0.087725, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.135857", "ticker_sentiment_score": "0.091173", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGPHF", "relevance_score": "0.090816", "ticker_sentiment_score": "0.093419", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/pressreleases/24/05/g38623996/aileron-therapeutics-announces-closing-of-underwritten-registered-direct-offering-of-up-to-approxi", "time_published": "20240503T200500", "authors": ["Globe Newswire"], "summary": "AUSTIN, Texas, May 03, 2024 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics, Inc. ( \"Aileron\" ) ALRN, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the closing ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.999819"}], "overall_sentiment_score": 0.104246, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.130689", "ticker_sentiment_score": "0.0893", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGPHF", "relevance_score": "0.087344", "ticker_sentiment_score": "0.088583", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/pressreleases/24/05/g38549401/aileron-therapeutics-announces-pricing-of-underwritten-registered-direct-offering-priced-at-the-ma", "time_published": "20240501T124503", "authors": ["Globe Newswire"], "summary": "AUSTIN, Texas, May 01, 2024 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics, Inc. ( \"Aileron\" ) ALRN, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the pricing ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.999819"}], "overall_sentiment_score": 0.106582, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.123951", "ticker_sentiment_score": "0.09036", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGPHF", "relevance_score": "0.08282", "ticker_sentiment_score": "0.098067", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million", "url": "https://www.globenewswire.com/news-release/2024/05/01/2873263/28652/en/Aileron-Therapeutics-Announces-Pricing-of-Underwritten-Registered-Direct-Offering-Priced-At-The-Market-Under-Nasdaq-Rules-of-up-to-Approximately-40-Million.html", "time_published": "20240501T124500", "authors": ["Aileron Therapeutics", "Inc."], "summary": "Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.999491"}], "overall_sentiment_score": 0.094816, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.129983", "ticker_sentiment_score": "0.093706", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGPHF", "relevance_score": "0.08687", "ticker_sentiment_score": "0.10193", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis  ( IPF ) ", "url": "https://www.globenewswire.com/news-release/2024/05/01/2873251/28652/en/Aileron-Therapeutics-Announces-Positive-Data-from-Cohort-1-of-the-Phase-1b-Clinical-Trial-of-LTI-03-in-Idiopathic-Pulmonary-Fibrosis-IPF.html", "time_published": "20240501T123000", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "Low-dose LTI-03 ( 2.5 mg BID ) , a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.109196, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.091162", "ticker_sentiment_score": "0.053925", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2024/04/15/2863221/28652/en/Aileron-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html", "time_published": "20240415T212000", "authors": ["Aileron Therapeutics", "Inc."], "summary": "Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.961735"}], "overall_sentiment_score": 0.148543, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.102668", "ticker_sentiment_score": "0.083735", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/pressreleases/24/02/g37167884/aileron-therapeutics-and-pulmonary-care-experts-to-discuss-the-potential-implications-of-lti-03-fo", "time_published": "20240215T210500", "authors": ["Globe Newswire"], "summary": "WALTHAM, Mass., Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics, Inc. ( \"Aileron\" ) ALRN, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, will host a virtual key ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.961735"}], "overall_sentiment_score": 0.14196, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.111358", "ticker_sentiment_score": "0.057395", "ticker_sentiment_label": "Neutral"}]}, {"title": "TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development", "url": "https://www.globenewswire.com/news-release/2024/02/06/2824126/0/en/TScan-Therapeutics-Expands-Clinical-Team-with-the-Appointment-of-Dawn-Pinchasik-M-D-M-S-as-Vice-President-Clinical-Development.html", "time_published": "20240206T120000", "authors": ["TScan Therapeutics", "Inc."], "summary": "WALTHAM, Mass., Feb. 06, 2024 ( GLOBE NEWSWIRE ) -- TScan Therapeutics, Inc. ( Nasdaq: TCRX ) , a clinical-stage biopharmaceutical company focused on the development of T cell receptor ( TCR ) -engineered T cell therapies ( TCR-T ) for the treatment of patients with cancer, today announced the ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d8d2632e-0ce4-4ed2-940e-22a1c599d43f", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.178861, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.036926", "ticker_sentiment_score": "0.045711", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.036926", "ticker_sentiment_score": "0.045711", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCRX", "relevance_score": "0.073773", "ticker_sentiment_score": "-0.038691", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/pressreleases/24/02/g36899474/aileron-therapeutics-to-host-key-opinion-leader-event-on-february-15-2024", "time_published": "20240201T213050", "authors": ["Globe Newswire"], "summary": "WALTHAM, Mass., Feb. 01, 2024 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics, Inc. ( \"Aileron\" ) ALRN, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.178535, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.264897", "ticker_sentiment_score": "0.172371", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024", "url": "https://www.globenewswire.com/news-release/2024/02/01/2822483/28652/en/Aileron-Therapeutics-to-Host-Key-Opinion-Leader-Event-on-February-15-2024.html", "time_published": "20240201T213000", "authors": ["Aileron Therapeutics", "Inc."], "summary": "Panel discussion will highlight LTI-03, Aileron's novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis Panel discussion will highlight LTI-03, Aileron's novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.190345, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.279015", "ticker_sentiment_score": "0.181639", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Getaround Shares Are Trading Higher By Around 86%; Here Are 20 Stocks Moving Premarket - Aileron Therapeutics  ( NASDAQ:ALRN ) , Aadi Bioscience  ( NASDAQ:AADI ) ", "url": "https://www.benzinga.com/news/23/12/36255748/why-getaround-shares-are-trading-higher-by-around-86-here-are-20-stocks-moving-premarket", "time_published": "20231215T131709", "authors": ["Avi Kapoor"], "summary": "Shares of Getaround, Inc. GETR rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter financial results. Getaround posted a quarterly loss of 29 cents per share, versus a year-ago loss of $1.3 per share.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/15/image20.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.865346"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.142745, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGRX", "relevance_score": "0.159043", "ticker_sentiment_score": "-0.412081", "ticker_sentiment_label": "Bearish"}, {"ticker": "IONM", "relevance_score": "0.159043", "ticker_sentiment_score": "0.05034", "ticker_sentiment_label": "Neutral"}, {"ticker": "LU", "relevance_score": "0.159043", "ticker_sentiment_score": "-0.088348", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRPX", "relevance_score": "0.159043", "ticker_sentiment_score": "-0.144794", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRLI", "relevance_score": "0.159043", "ticker_sentiment_score": "0.484568", "ticker_sentiment_label": "Bullish"}, {"ticker": "DTC", "relevance_score": "0.159043", "ticker_sentiment_score": "0.321774", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCHL", "relevance_score": "0.159043", "ticker_sentiment_score": "0.077781", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCPL", "relevance_score": "0.159043", "ticker_sentiment_score": "0.204199", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NIR", "relevance_score": "0.159043", "ticker_sentiment_score": "0.383146", "ticker_sentiment_label": "Bullish"}, {"ticker": "FRGT", "relevance_score": "0.236588", "ticker_sentiment_score": "0.239391", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALRN", "relevance_score": "0.159043", "ticker_sentiment_score": "-0.06268", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSC", "relevance_score": "0.236588", "ticker_sentiment_score": "-0.061855", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSCS", "relevance_score": "0.159043", "ticker_sentiment_score": "0.251512", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AADI", "relevance_score": "0.159043", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "EOSE", "relevance_score": "0.159043", "ticker_sentiment_score": "-0.197608", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GETR", "relevance_score": "0.311829", "ticker_sentiment_score": "0.144172", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLAY", "relevance_score": "0.236588", "ticker_sentiment_score": "0.433186", "ticker_sentiment_label": "Bullish"}]}, {"title": "Aileron Therapeutics Director Awarded $6K Worth of Stock Options - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/news/23/11/35593345/aileron-therapeutics-director-awarded-6k-worth-of-stock-options", "time_published": "20231103T150017", "authors": ["Benzinga Insights"], "summary": "Alan Musso, Director at Aileron Therapeutics ALRN, reported a large acquisition of company stock options on November 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}], "overall_sentiment_score": 0.245853, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.52706", "ticker_sentiment_score": "0.552281", "ticker_sentiment_label": "Bullish"}]}, {"title": "Aileron Therapeutics Board Member Awarded $6K Worth of Stock Options - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/news/23/11/35593339/aileron-therapeutics-board-member-awarded-6k-worth-of-stock-options", "time_published": "20231103T150012", "authors": ["Benzinga Insights"], "summary": "William Fairey, Board Member at Aileron Therapeutics ALRN, reported a large acquisition of company stock options on November 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}], "overall_sentiment_score": 0.245824, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.522854", "ticker_sentiment_score": "0.543302", "ticker_sentiment_label": "Bullish"}]}, {"title": "Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo", "url": "https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html", "time_published": "20231004T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Assesses ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.128467, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SYRS", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLTO", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPHA", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.065268", "ticker_sentiment_score": "-0.0392", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.065268", "ticker_sentiment_score": "-0.0392", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.042655", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVBXF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEM", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "INBX", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBPHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.086948", "ticker_sentiment_score": "-0.051258", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCM", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLM", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRDF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.086948", "ticker_sentiment_score": "-0.040696", "ticker_sentiment_label": "Neutral"}, {"ticker": "SURF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYSI", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAIN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.065268", "ticker_sentiment_score": "-0.046141", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIL", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBIO", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.10057", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYPHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVSQ", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "IUGNF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPHLF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 5 Health Care Stocks That May Collapse In Q2 - Aileron Therapeutics  ( NASDAQ:ALRN ) , Acumen Pharmaceuticals  ( NASDAQ:ABOS ) ", "url": "https://www.benzinga.com/news/23/05/32312863/top-5-health-care-stocks-that-may-collapse-in-q2", "time_published": "20230510T115329", "authors": ["Lisa Levin"], "summary": "The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/10/image15.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.264421, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.275867", "ticker_sentiment_score": "-0.014834", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCRX", "relevance_score": "0.275867", "ticker_sentiment_score": "0.238056", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABOS", "relevance_score": "0.275867", "ticker_sentiment_score": "0.272873", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAVA", "relevance_score": "0.275867", "ticker_sentiment_score": "0.16553", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bears are Losing Control Over Aileron Therapeutics, Inc.  ( ALRN ) , Here's Why It's a 'Buy' Now", "url": "https://www.zacks.com/stock/news/2074297/bears-are-losing-control-over-aileron-therapeutics-inc-alrn-heres-why-its-a-buy-now", "time_published": "20230404T135503", "authors": ["Zacks Investment Research"], "summary": "After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.230094, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.414559", "ticker_sentiment_score": "0.438377", "ticker_sentiment_label": "Bullish"}]}, {"title": "Aileron Therapeutics, Inc.  ( ALRN )  Could Find a Support Soon, Here's Why You Should Buy the Stock Now", "url": "https://www.zacks.com/stock/news/2065420/aileron-therapeutics-inc-alrn-could-find-a-support-soon-heres-why-you-should-buy-the-stock-now", "time_published": "20230314T135507", "authors": ["Zacks Investment Research"], "summary": "Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default45.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.219176, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.415699", "ticker_sentiment_score": "0.415262", "ticker_sentiment_label": "Bullish"}]}, {"title": "Looking Into Aileron Therapeutics's Recent Short Interest - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/short-sellers/23/03/31195419/looking-into-aileron-therapeuticss-recent-short-interest", "time_published": "20230303T183207", "authors": ["Benzinga Insights"], "summary": "Aileron Therapeutics's ALRN short percent of float has risen 50.0% since its last report. The company recently reported that it has 30 thousand shares sold short, which is 0.84% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_3986.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "S&P 500 Down 2%; Mobilicom Shares Spike Higher - Aileron Therapeutics  ( NASDAQ:ALRN ) , Arbe Robotics  ( NASDAQ:ARBE ) ", "url": "https://www.benzinga.com/news/earnings/23/02/30994277/s-p-500-down-2-mobilicom-shares-spike-higher", "time_published": "20230221T192423", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 2% on Tuesday. The Dow traded down 2.06% to 33,129.04 while the NASDAQ fell 2.39% to 11,506.10. The S&P 500 also fell, dropping, 2.05% to 3,995.66. Energy shares rose around 0.1% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/21/image24.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": -0.064452, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HCDI", "relevance_score": "0.123844", "ticker_sentiment_score": "0.104414", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOB", "relevance_score": "0.123844", "ticker_sentiment_score": "0.150417", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HLX", "relevance_score": "0.123844", "ticker_sentiment_score": "0.269975", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVRX", "relevance_score": "0.123844", "ticker_sentiment_score": "0.109031", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.123844", "ticker_sentiment_score": "-0.130264", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.359881", "ticker_sentiment_score": "0.019935", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARBE", "relevance_score": "0.184834", "ticker_sentiment_score": "0.231555", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GASS", "relevance_score": "0.123844", "ticker_sentiment_score": "0.269975", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EFTR", "relevance_score": "0.123844", "ticker_sentiment_score": "-0.192361", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.06211", "ticker_sentiment_score": "-0.280552", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:FIL", "relevance_score": "0.06211", "ticker_sentiment_score": "-0.280552", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why Aileron Therapeutics  ( ALRN )  Stock Is Plunging Today - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/general/biotech/23/02/30989090/aileron-therapeutics-shelves-development-on-chemoprotection-agent-shares-fall", "time_published": "20230221T175027", "authors": ["Vandana Singh"], "summary": "Aileron Therapeutics ALRN announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in p53-mutated breast cancer showed severe neutropenia ( Grade 4 ) and alopecia ( hair loss ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/21/alrn_logo_light__fe1fe357300c618d6ff9411bf9a464e2.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.225659, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.837089", "ticker_sentiment_score": "-0.539474", "ticker_sentiment_label": "Bearish"}]}, {"title": "Dow Tumbles More Than 500 Points; US Manufacturing PMI Rises In February - Aileron Therapeutics  ( NASDAQ:ALRN ) , Arbe Robotics  ( NASDAQ:ARBE ) ", "url": "https://www.benzinga.com/news/earnings/23/02/30992180/dow-tumbles-more-than-500-points-us-manufacturing-pmi-rises-in-february", "time_published": "20230221T171033", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 500 points on Tuesday. The Dow traded down 1.61% to 33,280.92 while the NASDAQ fell 2.05% to 11,545.79. The S&P 500 also fell, dropping, 1.65% to 4,011.67. Energy shares rose around 0.1% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/21/image38.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": -0.06446, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HCDI", "relevance_score": "0.123844", "ticker_sentiment_score": "0.104414", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOB", "relevance_score": "0.123844", "ticker_sentiment_score": "0.150417", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRMD", "relevance_score": "0.123844", "ticker_sentiment_score": "0.269975", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HLX", "relevance_score": "0.123844", "ticker_sentiment_score": "0.269975", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVRX", "relevance_score": "0.123844", "ticker_sentiment_score": "0.109031", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.123844", "ticker_sentiment_score": "-0.130264", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.359881", "ticker_sentiment_score": "0.019935", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARBE", "relevance_score": "0.184834", "ticker_sentiment_score": "0.231555", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EFTR", "relevance_score": "0.123844", "ticker_sentiment_score": "-0.192361", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.06211", "ticker_sentiment_score": "-0.280552", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:FIL", "relevance_score": "0.06211", "ticker_sentiment_score": "-0.280552", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Nasdaq Drops Over 100 Points; Walmart Issues Cautious Forecast - Aileron Therapeutics  ( NASDAQ:ALRN ) , Arbe Robotics  ( NASDAQ:ARBE ) ", "url": "https://www.benzinga.com/news/earnings/23/02/30989395/nasdaq-drops-over-100-points-walmart-issues-cautious-forecast", "time_published": "20230221T151506", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday. Following the market opening Tuesday, The Dow traded down 1.15% to 33,438.86 while the NASDAQ fell 1.24% to 11,640.85. The S&P 500 also fell, dropping, 1.03% to 4,037.11.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/21/image-walmart.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": -0.059846, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HCDI", "relevance_score": "0.113866", "ticker_sentiment_score": "0.100858", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOB", "relevance_score": "0.113866", "ticker_sentiment_score": "0.144914", "ticker_sentiment_label": "Neutral"}, {"ticker": "BORR", "relevance_score": "0.113866", "ticker_sentiment_score": "0.172826", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HLX", "relevance_score": "0.113866", "ticker_sentiment_score": "0.172826", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVRX", "relevance_score": "0.113866", "ticker_sentiment_score": "0.105318", "ticker_sentiment_label": "Neutral"}, {"ticker": "OKYO", "relevance_score": "0.170075", "ticker_sentiment_score": "-0.1389", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.113866", "ticker_sentiment_score": "-0.125086", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.279653", "ticker_sentiment_score": "0.018428", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARBE", "relevance_score": "0.170075", "ticker_sentiment_score": "0.218727", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.170075", "ticker_sentiment_score": "0.023149", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.057079", "ticker_sentiment_score": "-0.278835", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:FIL", "relevance_score": "0.057079", "ticker_sentiment_score": "-0.278835", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives", "url": "https://www.globenewswire.com/news-release/2023/02/21/2612166/28652/en/Aileron-Therapeutics-Announces-Termination-of-Phase-1b-Breast-Cancer-Chemoprotection-Trial-and-Exploration-of-Strategic-Alternatives.html", "time_published": "20230221T133000", "authors": ["Aileron Therapeutics", "Inc."], "summary": "BOSTON, Feb. 21, 2023 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia ( Grade ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.055316, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.644385", "ticker_sentiment_score": "0.037057", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Makes Aileron Therapeutics, Inc.  ( ALRN )  a New Buy Stock", "url": "https://www.zacks.com/stock/news/2033582/what-makes-aileron-therapeutics-inc-alrn-a-new-buy-stock", "time_published": "20221229T170006", "authors": ["Zacks Investment Research"], "summary": "Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default304.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}], "overall_sentiment_score": 0.30584, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.361626", "ticker_sentiment_score": "0.359944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/pressreleases/22/11/g29902484/aileron-therapeutics-regains-compliance-with-nasdaq-listing-requirements", "time_published": "20221130T120034", "authors": ["Globe Newswire"], "summary": "BOSTON, Nov. 30, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ALRN, a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.23163, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.514619", "ticker_sentiment_score": "0.316641", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements", "url": "https://www.globenewswire.com/news-release/2022/11/30/2564828/28652/en/Aileron-Therapeutics-Regains-Compliance-with-Nasdaq-Listing-Requirements.html", "time_published": "20221130T120000", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "BOSTON, Nov. 30, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that it received written notice on November 28, 2022 from The ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.238633, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.521812", "ticker_sentiment_score": "0.322141", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aileron Therapeutics, Inc.  ( ALRN )  May Find a Bottom Soon, Here's Why You Should Buy the Stock Now", "url": "https://www.zacks.com/stock/news/2021878/aileron-therapeutics-inc-alrn-may-find-a-bottom-soon-heres-why-you-should-buy-the-stock-now", "time_published": "20221124T145505", "authors": ["Zacks Investment Research"], "summary": "Aileron Therapeutics, Inc. (ALRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default53.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.207668, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.423843", "ticker_sentiment_score": "0.444223", "ticker_sentiment_label": "Bullish"}]}, {"title": "Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split", "url": "https://www.globenewswire.com/news-release/2022/11/10/2553192/28652/en/Aileron-Therapeutics-Announces-a-1-for-20-Reverse-Stock-Split.html", "time_published": "20221110T130000", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022 Common Stock Will Begin Trading on Split-Adjusted Basis on November ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.222121, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.417053", "ticker_sentiment_score": "0.255738", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMSQF", "relevance_score": "0.039811", "ticker_sentiment_score": "0.007917", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights", "url": "https://www.globenewswire.com/news-release/2022/11/01/2545485/28652/en/Aileron-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Business-Highlights.html", "time_published": "20221101T121500", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "BOSTON, Nov. 01, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives today, reported financial results and business highlights for the third quarter ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.050495, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.518618", "ticker_sentiment_score": "0.085128", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.024421", "ticker_sentiment_score": "-0.02304", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference", "url": "https://www.globenewswire.com/news-release/2022/10/26/2541580/28652/en/Aileron-Therapeutics-Presents-Results-from-Phase-1-Study-in-Healthy-Volunteers-Demonstrating-ALRN-6924-Induced-Cell-Cycle-Arrest-in-Bone-Marrow-Stem-Cells-and-Hair-Follicles-at-EOR.html", "time_published": "20221026T100500", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "BOSTON, Oct. 26, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented detailed results from its completed Phase 1 study of ALRN-6924 in ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.110354, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.705237", "ticker_sentiment_score": "0.197619", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022 - Aileron Therapeutics  ( NASDAQ:ALRN ) ", "url": "https://www.benzinga.com/pressreleases/22/09/g29093722/aileron-therapeutics-announces-oral-presentation-of-non-clinical-data-demonstrating-alrn-6924-prot", "time_published": "20220930T124129", "authors": ["Globe Newswire"], "summary": "ALRN-6924 temporarily arrested the cell cycle in human scalp hair follicles and their stem cells Ex vivo data demonstrated protection against taxane-induced damage to hair follicles and their stem cells", "banner_image": "", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.089429, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.522333", "ticker_sentiment_score": "0.208274", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022", "url": "https://www.globenewswire.com/news-release/2022/09/30/2526018/28652/en/Aileron-Therapeutics-Announces-Oral-Presentation-of-Non-Clinical-Data-Demonstrating-ALRN-6924-Protected-Human-Hair-Follicles-and-Their-Stem-Cells-from-Chemotherapy-Induced-Damage-a.html", "time_published": "20220930T124100", "authors": ["Aileron Therapeutics", "Inc."], "summary": "BOSTON, Sept. 30, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced an oral presentation at the European Society for Dermatological ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.075159, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.519532", "ticker_sentiment_score": "0.17634", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": " ( ALRN )  - Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference", "url": "https://www.benzinga.com/pressreleases/22/09/g28753047/aileron-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference", "time_published": "20220906T110024", "authors": ["Globe Newswire"], "summary": "BOSTON, Sept. 06, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ALRN, a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that a pre-recorded corporate presentation by Manuel Aivado, M.D., Ph.D., ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.196069, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.544495", "ticker_sentiment_score": "0.291822", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference", "url": "https://www.globenewswire.com/news-release/2022/09/06/2510220/28652/en/Aileron-Therapeutics-to-Present-at-the-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html", "time_published": "20220906T110000", "authors": ["Aileron Therapeutics", "Inc."], "summary": "BOSTON, Sept. 06, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that a pre-recorded corporate presentation by Manuel Aivado, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.203523, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.565345", "ticker_sentiment_score": "0.300925", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights", "url": "https://www.globenewswire.com/news-release/2022/08/15/2498582/28652/en/Aileron-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Business-Highlights.html", "time_published": "20220815T201500", "authors": ["Aileron Therapeutics", "Inc."], "summary": "BOSTON, Aug. 15, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives today, reported financial results and business highlights for the second quarter ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.110094, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.514619", "ticker_sentiment_score": "0.180783", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HRMY", "relevance_score": "0.022264", "ticker_sentiment_score": "0.017493", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Marker Therapeutics Trading Higher By 119%: Here Are 42 Stocks Moving Premarket", "url": "https://www.benzinga.com/news/22/08/28373054/why-is-marker-therapeutics-trading-higher-by-119-here-are-42-stocks-moving-premarket", "time_published": "20220805T113501", "authors": ["Lisa Levin"], "summary": "Assure Holdings Corp. IONM shares rose 141.4% to $5.07 in pre-market trading after jumping around 104% on Thursday. Marker Therapeutics, Inc. MRKR shares rose 119% to $0.7248 in pre-market trading. The U.S.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/05/image_1.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.997787"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.998932"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.036006, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ATCO", "relevance_score": "0.094266", "ticker_sentiment_score": "0.224105", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMTD", "relevance_score": "0.062926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGY", "relevance_score": "0.094266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QNRX", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.044604", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.031487", "ticker_sentiment_score": "-0.155732", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SMFL", "relevance_score": "0.062926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPS", "relevance_score": "0.062926", "ticker_sentiment_score": "0.250422", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IONM", "relevance_score": "0.062926", "ticker_sentiment_score": "0.128077", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNLN", "relevance_score": "0.094266", "ticker_sentiment_score": "0.043753", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOBR", "relevance_score": "0.062926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.062926", "ticker_sentiment_score": "0.064291", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVIV", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.188203", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMC", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.261471", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EVFM", "relevance_score": "0.062926", "ticker_sentiment_score": "0.297655", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACMR", "relevance_score": "0.062926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPCE", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.16715", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "Z", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.214283", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ACOR", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.290616", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DOCS", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.123409", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.130081", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACON", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.061512", "ticker_sentiment_label": "Neutral"}, {"ticker": "NERV", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.044604", "ticker_sentiment_label": "Neutral"}, {"ticker": "STAF", "relevance_score": "0.062926", "ticker_sentiment_score": "0.26348", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CEMI", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.046701", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATNX", "relevance_score": "0.094266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BARK", "relevance_score": "0.062926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYZN", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.164144", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRKR", "relevance_score": "0.094266", "ticker_sentiment_score": "0.057454", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEDS", "relevance_score": "0.062926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMC", "relevance_score": "0.062926", "ticker_sentiment_score": "0.196226", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACLTF", "relevance_score": "0.031487", "ticker_sentiment_score": "0.203851", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DRRX", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.261471", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ACRX", "relevance_score": "0.094266", "ticker_sentiment_score": "0.095236", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGTX", "relevance_score": "0.094266", "ticker_sentiment_score": "-0.018043", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.012248", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVNA", "relevance_score": "0.062926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSDT", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.176172", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NET", "relevance_score": "0.062926", "ticker_sentiment_score": "0.301678", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FUBO", "relevance_score": "0.062926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer", "url": "https://www.globenewswire.com/news-release/2022/08/01/2489315/28652/en/Aileron-Therapeutics-Is-Pleased-to-Outline-Strategy-to-Strengthen-Phase-1b-Clinical-Trial-of-ALRN-6924-in-Patients-with-p53-Mutated-Breast-Cancer.html", "time_published": "20220801T115100", "authors": ["Aileron Therapeutics", "Inc."], "summary": "BOSTON, Aug. 01, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today outlined its strategy to strengthen the company's Phase 1b chemoprotection ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.043693, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.569808", "ticker_sentiment_score": "0.06973", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022", "url": "https://www.benzinga.com/pressreleases/22/07/g27998908/aileron-therapeutics-to-participate-in-fireside-chat-at-the-william-blair-biotech-focus-conference", "time_published": "20220708T123106", "authors": ["Globe Newswire"], "summary": "BOSTON, July 08, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ALRN, a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.041176, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.501722", "ticker_sentiment_score": "0.058238", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022", "url": "https://www.globenewswire.com/news-release/2022/07/08/2476580/28652/en/Aileron-Therapeutics-to-Participate-in-Fireside-Chat-at-the-William-Blair-Biotech-Focus-Conference-2022.html", "time_published": "20220708T123100", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "BOSTON, July 08, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.105407, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.523063", "ticker_sentiment_score": "0.105407", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Aileron Shares Are Falling Today", "url": "https://www.benzinga.com/general/biotech/22/06/27900396/aileron-shares-fall-after-early-data-from-chemoprotective-agent-in-lung-cancer-setting", "time_published": "20220629T134637", "authors": ["Vandana Singh"], "summary": "Aileron Therapeutics ALRN announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer ( NSCLC ) undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/29/aapharma_8.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.015055, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.887793", "ticker_sentiment_score": "0.007517", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer  ( NSCLC )  and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer", "url": "https://www.globenewswire.com/news-release/2022/06/29/2471088/28652/en/Aileron-Therapeutics-Announces-Interim-Data-from-Phase-1b-Chemoprotection-Trial-of-ALRN-6924-in-Patients-with-p53-Mutated-Non-Small-Cell-Lung-Cancer-NSCLC-and-Confirms-Development-.html", "time_published": "20220629T103000", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "BOSTON, June 29, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced interim data from its Phase 1b chemoprotection trial of patients ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.082272, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.493024", "ticker_sentiment_score": "0.085167", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer", "url": "https://www.benzinga.com/pressreleases/22/05/g27296473/aileron-therapeutics-announces-first-patients-treated-in-phase-1b-trial-of-alrn-6924-in-patients-w", "time_published": "20220519T110000", "authors": ["Globe Newswire"], "summary": "Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities Trial is evaluating ALRN-6924 as a treatment to prevent chemotherapy-induced neutropenia, other bone marrow toxicities, and toxicities outside of the", "banner_image": "https://ml.globenewswire.com/media/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d/small/aileron-logo-png.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.071869, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.591306", "ticker_sentiment_score": "0.078265", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer", "url": "https://www.globenewswire.com/news-release/2022/05/19/2446755/28652/en/Aileron-Therapeutics-Announces-First-Patients-Treated-in-Phase-1b-Trial-of-ALRN-6924-in-Patients-with-p53-Mutated-Neoadjuvant-Breast-Cancer.html", "time_published": "20220519T110000", "authors": ["Aileron Therapeutics", "Inc."], "summary": "BOSTON, May 19, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced it has treated the first patients in its Phase 1b randomized, co", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.060752, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.482315", "ticker_sentiment_score": "0.060752", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022", "url": "https://www.benzinga.com/pressreleases/22/05/g27185424/aileron-therapeutics-to-host-virtual-kol-investor-event-on-may-19-2022", "time_published": "20220513T110030", "authors": ["Globe Newswire"], "summary": "BOSTON, May 13, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( NASDAQ:ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that it will host a virtual KOL investor event on Thursday, May 1", "banner_image": "https://ml.globenewswire.com/media/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d/small/aileron-logo-png.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.054013, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.527457", "ticker_sentiment_score": "0.070557", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022", "url": "https://www.globenewswire.com/news-release/2022/05/13/2442904/28652/en/Aileron-Therapeutics-to-Host-Virtual-KOL-Investor-Event-on-May-19-2022.html", "time_published": "20220513T110000", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "BOSTON, May 13, 2022 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that it will host a virtual KOL investor event on Thursday, May", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.045271, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.36475", "ticker_sentiment_score": "0.045271", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting", "url": "https://www.benzinga.com/pressreleases/22/05/g27116271/aileron-therapeutics-announces-late-breaking-oral-presentation-of-non-clinical-data-demonstrating-", "time_published": "20220510T164327", "authors": ["Globe Newswire"], "summary": "Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss  ( alopecia ) \nNew non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles and their stem cells\nALRN-6924-induced cel", "banner_image": "https://ml.globenewswire.com/media/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d/small/aileron-logo-png.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.090685, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.544495", "ticker_sentiment_score": "0.094266", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting", "url": "https://www.globenewswire.com/news-release/2022/05/10/2440078/28652/en/Aileron-Therapeutics-Announces-Late-Breaking-Oral-Presentation-of-Non-Clinical-Data-Demonstrating-ALRN-6924-Protected-Human-Hair-Follicles-and-Their-Stem-Cells-from-Chemotherapy-In.html", "time_published": "20220510T164300", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "BOSTON, May  10, 2022   ( GLOBE NEWSWIRE )  -- Aileron Therapeutics  ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced a late-breaking oral presentation at the upcoming Society for In", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.091628, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.503586", "ticker_sentiment_score": "0.091628", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Aileron Therapeutics  ( ALRN )  Outperforming Other Medical Stocks This Year?", "url": "https://www.zacks.com/stock/news/1904282/is-aileron-therapeutics-alrn-outperforming-other-medical-stocks-this-year", "time_published": "20220421T134009", "authors": ["Zacks Investment Research"], "summary": "Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.065022, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FNA", "relevance_score": "0.459459", "ticker_sentiment_score": "0.071486", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.729361", "ticker_sentiment_score": "0.064647", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Aileron Therapeutics, Inc.  ( ALRN )  Stock Outpacing Its Medical Peers This Year?", "url": "https://www.zacks.com/stock/news/1893031/is-aileron-therapeutics-inc-alrn-stock-outpacing-its-medical-peers-this-year", "time_published": "20220405T134009", "authors": ["Zacks Investment Research"], "summary": "Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default154.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.151189, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.702247", "ticker_sentiment_score": "0.139742", "ticker_sentiment_label": "Neutral"}]}, {"title": "50 Biggest Movers From Yesterday", "url": "https://www.benzinga.com/news/22/03/26340073/50-biggest-movers-from-yesterday", "time_published": "20220329T091148", "authors": [], "summary": "Gainers\nHycroft Mining Holding Corporation  ( NASDAQ: HYMC )  shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in Hycroft Mining Holding.\nDatChat, Inc.  ( NASDAQ: DATS )  jumped 61.5% to close at $2.68 after the company announced it would", "banner_image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_421.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.010764, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BBBY", "relevance_score": "0.074437", "ticker_sentiment_score": "0.001778", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNLN", "relevance_score": "0.074437", "ticker_sentiment_score": "0.002207", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLTA", "relevance_score": "0.074437", "ticker_sentiment_score": "-0.627268", "ticker_sentiment_label": "Bearish"}, {"ticker": "VIEW", "relevance_score": "0.074437", "ticker_sentiment_score": "0.000678", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTLS", "relevance_score": "0.111453", "ticker_sentiment_score": "0.010483", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMC", "relevance_score": "0.111453", "ticker_sentiment_score": "0.005881", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNT", "relevance_score": "0.111453", "ticker_sentiment_score": "0.001845", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORIC", "relevance_score": "0.074437", "ticker_sentiment_score": "0.00179", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEGG", "relevance_score": "0.037259", "ticker_sentiment_score": "-0.020854", "ticker_sentiment_label": "Neutral"}, {"ticker": "GME", "relevance_score": "0.148228", "ticker_sentiment_score": "0.000256", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESOA", "relevance_score": "0.074437", "ticker_sentiment_score": "0.001457", "ticker_sentiment_label": "Neutral"}, {"ticker": "DATS", "relevance_score": "0.074437", "ticker_sentiment_score": "0.007707", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.074437", "ticker_sentiment_score": "0.000943", "ticker_sentiment_label": "Neutral"}, {"ticker": "IO", "relevance_score": "0.074437", "ticker_sentiment_score": "-0.001337", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLXE", "relevance_score": "0.074437", "ticker_sentiment_score": "0.000865", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVNO", "relevance_score": "0.111453", "ticker_sentiment_score": "0.009815", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRIN", "relevance_score": "0.074437", "ticker_sentiment_score": "0.002928", "ticker_sentiment_label": "Neutral"}, {"ticker": "THMO", "relevance_score": "0.074437", "ticker_sentiment_score": "0.002002", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.074437", "ticker_sentiment_score": "0.001107", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRIX", "relevance_score": "0.111453", "ticker_sentiment_score": "-0.003691", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTBT", "relevance_score": "0.074437", "ticker_sentiment_score": "0.00604", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONO", "relevance_score": "0.111453", "ticker_sentiment_score": "0.014864", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMHC", "relevance_score": "0.037259", "ticker_sentiment_score": "0.018369", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMNM", "relevance_score": "0.074437", "ticker_sentiment_score": "0.007817", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOSC", "relevance_score": "0.074437", "ticker_sentiment_score": "0.023342", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYMC", "relevance_score": "0.111453", "ticker_sentiment_score": "0.006792", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.074437", "ticker_sentiment_score": "0.000421", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMTC", "relevance_score": "0.074437", "ticker_sentiment_score": "0.000894", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANY", "relevance_score": "0.037259", "ticker_sentiment_score": "0.00212", "ticker_sentiment_label": "Neutral"}, {"ticker": "CALA", "relevance_score": "0.074437", "ticker_sentiment_score": "0.000659", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEXI", "relevance_score": "0.074437", "ticker_sentiment_score": "0.00054", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCBP", "relevance_score": "0.074437", "ticker_sentiment_score": "0.006784", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEXPF", "relevance_score": "0.037259", "ticker_sentiment_score": "0.00054", "ticker_sentiment_label": "Neutral"}, {"ticker": "DLNG", "relevance_score": "0.111453", "ticker_sentiment_score": "0.007047", "ticker_sentiment_label": "Neutral"}, {"ticker": "XCUR", "relevance_score": "0.111453", "ticker_sentiment_score": "0.004984", "ticker_sentiment_label": "Neutral"}, {"ticker": "BITF", "relevance_score": "0.074437", "ticker_sentiment_score": "0.007017", "ticker_sentiment_label": "Neutral"}, {"ticker": "STAA", "relevance_score": "0.074437", "ticker_sentiment_score": "0.014749", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRC", "relevance_score": "0.074437", "ticker_sentiment_score": "-2.6e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "POLY", "relevance_score": "0.074437", "ticker_sentiment_score": "0.010115", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELZ", "relevance_score": "0.111453", "ticker_sentiment_score": "0.020283", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEON", "relevance_score": "0.074437", "ticker_sentiment_score": "0.000701", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEGG", "relevance_score": "0.074437", "ticker_sentiment_score": "0.002245", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZME", "relevance_score": "0.074437", "ticker_sentiment_score": "-0.000163", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHIL", "relevance_score": "0.111453", "ticker_sentiment_score": "-4.3e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.074437", "ticker_sentiment_score": "0.000578", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVR", "relevance_score": "0.111453", "ticker_sentiment_score": "0.062015", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIOT", "relevance_score": "0.074437", "ticker_sentiment_score": "0.001987", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRN", "relevance_score": "0.074437", "ticker_sentiment_score": "0.002297", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAPR", "relevance_score": "0.074437", "ticker_sentiment_score": "0.008305", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.037259", "ticker_sentiment_score": "0.001987", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.037259", "ticker_sentiment_score": "0.001987", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights", "url": "https://www.globenewswire.com/news-release/2022/03/28/2411402/28652/en/Aileron-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Business-Highlights.html", "time_published": "20220328T202000", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "BOSTON, Mass., March  28, 2022   ( GLOBE NEWSWIRE )  -- Aileron Therapeutics  ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today reported business highlights and financial results for the fourth", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.164228, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.50114", "ticker_sentiment_score": "0.173113", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "35 Stocks Moving In Monday's Mid-Day Session", "url": "https://www.benzinga.com/news/22/03/26327227/35-stocks-moving-in-mondays-mid-day-session", "time_published": "20220328T161143", "authors": [], "summary": "Gainers\nHycroft Mining Holding Corporation  ( NASDAQ: HYMC )  jumped 57.1% to $1.96  following reports regarding potential future investments from AMC CEO, Adam Aron.\nPlantronics, Inc.  ( NYSE: POLY )  shares jumped 50% to $39.28 after HP announced it will acquire the company.\nB.O.S. Better Online S", "banner_image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_149.jpg", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.01645, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IMNM", "relevance_score": "0.103175", "ticker_sentiment_score": "0.008197", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOSC", "relevance_score": "0.103175", "ticker_sentiment_score": "0.037258", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYMC", "relevance_score": "0.103175", "ticker_sentiment_score": "0.004594", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.103175", "ticker_sentiment_score": "0.000421", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMTC", "relevance_score": "0.103175", "ticker_sentiment_score": "-0.000132", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADN", "relevance_score": "0.103175", "ticker_sentiment_score": "-0.002419", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLTA", "relevance_score": "0.103175", "ticker_sentiment_score": "-0.571376", "ticker_sentiment_label": "Bearish"}, {"ticker": "VIEW", "relevance_score": "0.103175", "ticker_sentiment_score": "6.5e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTLS", "relevance_score": "0.154224", "ticker_sentiment_score": "0.018822", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMC", "relevance_score": "0.154224", "ticker_sentiment_score": "0.003134", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNT", "relevance_score": "0.154224", "ticker_sentiment_score": "-0.006956", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORIC", "relevance_score": "0.103175", "ticker_sentiment_score": "0.000893", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEGG", "relevance_score": "0.051696", "ticker_sentiment_score": "-0.000284", "ticker_sentiment_label": "Neutral"}, {"ticker": "GME", "relevance_score": "0.204633", "ticker_sentiment_score": "6.6e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESOA", "relevance_score": "0.103175", "ticker_sentiment_score": "-0.000182", "ticker_sentiment_label": "Neutral"}, {"ticker": "DLNG", "relevance_score": "0.154224", "ticker_sentiment_score": "0.003052", "ticker_sentiment_label": "Neutral"}, {"ticker": "XCUR", "relevance_score": "0.154224", "ticker_sentiment_score": "0.003337", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.103175", "ticker_sentiment_score": "0.000593", "ticker_sentiment_label": "Neutral"}, {"ticker": "BITF", "relevance_score": "0.103175", "ticker_sentiment_score": "0.000267", "ticker_sentiment_label": "Neutral"}, {"ticker": "IO", "relevance_score": "0.103175", "ticker_sentiment_score": "-0.00273", "ticker_sentiment_label": "Neutral"}, {"ticker": "STAA", "relevance_score": "0.103175", "ticker_sentiment_score": "0.007838", "ticker_sentiment_label": "Neutral"}, {"ticker": "POLY", "relevance_score": "0.103175", "ticker_sentiment_score": "0.00742", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLXE", "relevance_score": "0.103175", "ticker_sentiment_score": "9.8e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVNO", "relevance_score": "0.154224", "ticker_sentiment_score": "0.004923", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELZ", "relevance_score": "0.154224", "ticker_sentiment_score": "0.014847", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHIL", "relevance_score": "0.154224", "ticker_sentiment_score": "-0.000142", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.103175", "ticker_sentiment_score": "0.000234", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.103175", "ticker_sentiment_score": "0.000315", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVR", "relevance_score": "0.154224", "ticker_sentiment_score": "0.02409", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRIX", "relevance_score": "0.154224", "ticker_sentiment_score": "-0.003962", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIOT", "relevance_score": "0.103175", "ticker_sentiment_score": "0.003047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTBT", "relevance_score": "0.103175", "ticker_sentiment_score": "0.000385", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONO", "relevance_score": "0.154224", "ticker_sentiment_score": "0.026846", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMHC", "relevance_score": "0.051696", "ticker_sentiment_score": "0.00506", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAPR", "relevance_score": "0.103175", "ticker_sentiment_score": "-0.002655", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.051696", "ticker_sentiment_score": "0.003047", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.051696", "ticker_sentiment_score": "0.003047", "ticker_sentiment_label": "Neutral"}]}, {"title": "22 Stocks Moving in Monday's Pre-Market Session", "url": "https://www.benzinga.com/markets/penny-stocks/22/03/26316998/22-stocks-moving-in-mondays-pre-market-session", "time_published": "20220328T103414", "authors": ["Lisa Levin"], "summary": "Gainers\nHycroft Mining Holding Corporation  ( NASDAQ: HYMC )  rose 27.3% to $1.63 in pre-market trading. Last week, AMC Entertainment Holdings purchased a major stake in Hycroft Mining Holding.\nDynagas LNG Partners LP  ( NYSE: DLNG )  shares rose 19.1% to $4.16 in pre-market trading after jumping 16", "banner_image": "https://cdn.benzinga.com/files/images/story/2012/premkt_movers_582.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.882182"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.00329, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DLNG", "relevance_score": "0.219676", "ticker_sentiment_score": "0.002199", "ticker_sentiment_label": "Neutral"}, {"ticker": "XCUR", "relevance_score": "0.219676", "ticker_sentiment_score": "0.001419", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYMC", "relevance_score": "0.219676", "ticker_sentiment_score": "0.002827", "ticker_sentiment_label": "Neutral"}, {"ticker": "BITF", "relevance_score": "0.147501", "ticker_sentiment_score": "0.000494", "ticker_sentiment_label": "Neutral"}, {"ticker": "IO", "relevance_score": "0.147501", "ticker_sentiment_score": "-0.001802", "ticker_sentiment_label": "Neutral"}, {"ticker": "VEON", "relevance_score": "0.147501", "ticker_sentiment_score": "0.000649", "ticker_sentiment_label": "Neutral"}, {"ticker": "STAA", "relevance_score": "0.147501", "ticker_sentiment_score": "0.004843", "ticker_sentiment_label": "Neutral"}, {"ticker": "FINV", "relevance_score": "0.147501", "ticker_sentiment_score": "0.001333", "ticker_sentiment_label": "Neutral"}, {"ticker": "PALI", "relevance_score": "0.219676", "ticker_sentiment_score": "0.002613", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRLN", "relevance_score": "0.147501", "ticker_sentiment_score": "0.01072", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHS", "relevance_score": "0.147501", "ticker_sentiment_score": "-0.001105", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTLS", "relevance_score": "0.074069", "ticker_sentiment_score": "0.008109", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMC", "relevance_score": "0.074069", "ticker_sentiment_score": "0.002827", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTX", "relevance_score": "0.147501", "ticker_sentiment_score": "-0.000512", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.147501", "ticker_sentiment_score": "0.000874", "ticker_sentiment_label": "Neutral"}, {"ticker": "MF", "relevance_score": "0.147501", "ticker_sentiment_score": "0.003278", "ticker_sentiment_label": "Neutral"}, {"ticker": "REVB", "relevance_score": "0.219676", "ticker_sentiment_score": "0.003266", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEGG", "relevance_score": "0.074069", "ticker_sentiment_score": "-0.000227", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVR", "relevance_score": "0.219676", "ticker_sentiment_score": "0.033429", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTBT", "relevance_score": "0.147501", "ticker_sentiment_score": "0.000344", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONO", "relevance_score": "0.219676", "ticker_sentiment_score": "0.008109", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMHC", "relevance_score": "0.074069", "ticker_sentiment_score": "0.00432", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCTY", "relevance_score": "0.147501", "ticker_sentiment_score": "0.003413", "ticker_sentiment_label": "Neutral"}]}, {"title": "64 Biggest Movers From Friday", "url": "https://www.benzinga.com/news/22/03/26315719/64-biggest-movers-from-friday", "time_published": "20220328T080454", "authors": [], "summary": "Gainers\nClever Leaves Holdings Inc.  ( NASDAQ: CLVR )  shares surged 143% to settle at $3.84 on Friday after the company reported better-than-expected Q4 sales results and reaffirmed FY22 guidance.\nForge Global Holdings, Inc.   ( NYSE: FRGE )  shares climbed 50.2% to close at $18.70 on Friday.\nFresh", "banner_image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_420.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.108306, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OCFT", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000341", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNLN", "relevance_score": "0.090078", "ticker_sentiment_score": "0.005816", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUGE", "relevance_score": "0.060123", "ticker_sentiment_score": "0.001704", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.030083", "ticker_sentiment_score": "-0.000554", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRGE", "relevance_score": "0.060123", "ticker_sentiment_score": "0.004469", "ticker_sentiment_label": "Neutral"}, {"ticker": "CEIX", "relevance_score": "0.060123", "ticker_sentiment_score": "0.004236", "ticker_sentiment_label": "Neutral"}, {"ticker": "MULN", "relevance_score": "0.060123", "ticker_sentiment_score": "0.002396", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENFN", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.000687", "ticker_sentiment_label": "Neutral"}, {"ticker": "TLRY", "relevance_score": "0.060123", "ticker_sentiment_score": "0.006798", "ticker_sentiment_label": "Neutral"}, {"ticker": "BILI", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000345", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEIP", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.406804", "ticker_sentiment_label": "Bearish"}, {"ticker": "CODX", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000735", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPU", "relevance_score": "0.060123", "ticker_sentiment_score": "0.002655", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYRN", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.514785", "ticker_sentiment_label": "Bearish"}, {"ticker": "JUPW", "relevance_score": "0.060123", "ticker_sentiment_score": "0.001885", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAN", "relevance_score": "0.030083", "ticker_sentiment_score": "-0.000182", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRXT", "relevance_score": "0.060123", "ticker_sentiment_score": "0.001114", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURI", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.003171", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMTE", "relevance_score": "0.060123", "ticker_sentiment_score": "0.002569", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.060123", "ticker_sentiment_score": "0.001885", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMRT", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.450907", "ticker_sentiment_label": "Bearish"}, {"ticker": "ICLK", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.847251", "ticker_sentiment_label": "Bearish"}, {"ticker": "ASAN", "relevance_score": "0.090078", "ticker_sentiment_score": "0.000296", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLAR", "relevance_score": "0.030083", "ticker_sentiment_score": "0.001114", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLEU", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.010513", "ticker_sentiment_label": "Neutral"}, {"ticker": "RADA", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.000554", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEXI", "relevance_score": "0.060123", "ticker_sentiment_score": "0.001487", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONL", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000145", "ticker_sentiment_label": "Neutral"}, {"ticker": "RKDA", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000904", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMTI", "relevance_score": "0.060123", "ticker_sentiment_score": "0.001065", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEXT", "relevance_score": "0.090078", "ticker_sentiment_score": "0.006206", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTPI", "relevance_score": "0.060123", "ticker_sentiment_score": "0.003983", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPCB", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000106", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEXPF", "relevance_score": "0.030083", "ticker_sentiment_score": "0.001487", "ticker_sentiment_label": "Neutral"}, {"ticker": "CISO", "relevance_score": "0.060123", "ticker_sentiment_score": "0.001344", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUN", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000503", "ticker_sentiment_label": "Neutral"}, {"ticker": "DLNG", "relevance_score": "0.060123", "ticker_sentiment_score": "0.010353", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBP", "relevance_score": "0.060123", "ticker_sentiment_score": "0.005731", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOXD", "relevance_score": "0.060123", "ticker_sentiment_score": "0.004954", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGFY", "relevance_score": "0.090078", "ticker_sentiment_score": "-0.572059", "ticker_sentiment_label": "Bearish"}, {"ticker": "ARTW", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000763", "ticker_sentiment_label": "Neutral"}, {"ticker": "DIDI", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.000224", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWN", "relevance_score": "0.060123", "ticker_sentiment_score": "0.001066", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMC", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.100341", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGGF", "relevance_score": "0.030083", "ticker_sentiment_score": "-0.000554", "ticker_sentiment_label": "Neutral"}, {"ticker": "YSG", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000758", "ticker_sentiment_label": "Neutral"}, {"ticker": "CUTR", "relevance_score": "0.060123", "ticker_sentiment_score": "0.024865", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAVE", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000311", "ticker_sentiment_label": "Neutral"}, {"ticker": "PIK", "relevance_score": "0.060123", "ticker_sentiment_score": "0.003286", "ticker_sentiment_label": "Neutral"}, {"ticker": "GBNH", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000633", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.090078", "ticker_sentiment_score": "0.034785", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLG", "relevance_score": "0.060123", "ticker_sentiment_score": "0.000798", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVR", "relevance_score": "0.060123", "ticker_sentiment_score": "0.032672", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPST", "relevance_score": "0.060123", "ticker_sentiment_score": "0.010443", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMHI", "relevance_score": "0.060123", "ticker_sentiment_score": "0.036408", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.060123", "ticker_sentiment_score": "-0.158465", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JOBY", "relevance_score": "0.060123", "ticker_sentiment_score": "0.006095", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIR", "relevance_score": "0.060123", "ticker_sentiment_score": "0.001112", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Must-Watch Penny Stocks For Your April List", "url": "https://pennystocks.com/featured/2022/03/25/top-must-watch-penny-stocks-april-list/", "time_published": "20220325T200640", "authors": [], "summary": "Are these penny stocks on your April watchlist?\nThe post Top Must-Watch Penny Stocks For Your April List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.", "banner_image": "https://pennystocks.com/wp-content/uploads/2022/03/Penny_Stocks_to_Watch_Creative-Medical-Technology-CELZ-Stock-Chart.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.337703, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADMA", "relevance_score": "0.2796", "ticker_sentiment_score": "0.5312", "ticker_sentiment_label": "Bullish"}, {"ticker": "ALRN", "relevance_score": "0.094969", "ticker_sentiment_score": "0.595645", "ticker_sentiment_label": "Bullish"}, {"ticker": "CLVR", "relevance_score": "0.094969", "ticker_sentiment_score": "0.595645", "ticker_sentiment_label": "Bullish"}, {"ticker": "AGFY", "relevance_score": "0.234503", "ticker_sentiment_score": "0.119739", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference", "url": "https://www.benzinga.com/pressreleases/22/03/g26236846/aileron-therapeutics-to-participate-in-maxim-group-2022-virtual-growth-conference", "time_published": "20220322T120430", "authors": ["Globe Newswire"], "summary": "BOSTON, March  22, 2022   ( GLOBE NEWSWIRE )  -- Aileron Therapeutics  ( NASDAQ:ALRN ) , a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients' lives, announced today that Manuel Aivado, M.D., Ph.D., President", "banner_image": "https://ml.globenewswire.com/media/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d/small/aileron-logo-png.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.116905, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.50156", "ticker_sentiment_score": "0.063327", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference", "url": "https://www.globenewswire.com/news-release/2022/03/22/2407571/28652/en/Aileron-Therapeutics-to-Participate-in-Maxim-Group-2022-Virtual-Growth-Conference.html", "time_published": "20220322T120400", "authors": ["Inc.", "Aileron Therapeutics"], "summary": "BOSTON, March  22, 2022   ( GLOBE NEWSWIRE )  -- Aileron Therapeutics  ( Nasdaq: ALRN ) , a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients' lives, announced today that Manuel Aivado, M.D., Ph.D., Presiden", "banner_image": "https://ml.globenewswire.com/Resource/Download/0f820a8e-3c6b-47d8-bbd1-78d7a9ae490d?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.110565, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALRN", "relevance_score": "0.567024", "ticker_sentiment_score": "0.110565", "ticker_sentiment_label": "Neutral"}]}]}